Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 10 (October)

1. Reversal of experimental pulmonary hypertension by PDGF inhibition.
   J Clin Invest, 115(10): 2811-21. [Abstract] [Full-text]
2. Imatinib induces hypothyroidism in patients receiving levothyroxine.
   Clin Pharmacol Ther, 78(4): 433-8. [Abstract] [Full-text]
3. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
   Bone Marrow Transplant. [Abstract] [Full-text]
4. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
   Cancer Res, 65(19): 8912-9. [Abstract] [Full-text]
5. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
   Clin Cancer Res, 11(19): 6987-93. [Abstract] [Full-text]
6. Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
   Hematology, 10(5): 349-59. [Abstract] [Full-text]
7. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era.
   Am J Clin Pathol, 124(5): 740-8. [Abstract] [Full-text]
8. Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
   Semin Oncol, 32(4): 422-31. [Abstract] [Full-text]
9. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
   Blood, 106(8): 2865-70. [Abstract] [Full-text]
10. Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of human basophils.
    J Allergy Clin Immunol, 116(4): 820-6. [Abstract] [Full-text]
11. ABL1 amplification in T-cell acute lymphoblastic leukemia.
    Cancer Genet Cytogenet, 162(2): 146-50. [Abstract] [Full-text]
12. Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles.
    J Immunol Methods, 305(1): 59-66. [Abstract] [Full-text]
13. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
    Exp Hematol, 33(10): 1140-6. [Abstract] [Full-text]
14. Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
    Acta Haematol, 114(3): 150-4. [Abstract] [Full-text]
15. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
    J Am Acad Dermatol, 53(5): S240-3. [Abstract] [Full-text]
16. Anti-tumour activity of zoledronic acid.
    Cancer Treat Rev. [Abstract] [Full-text]
17. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Cancer Res, 65(20): 9436-44. [Abstract] [Full-text]
18. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    J Clin Oncol, 23(30): 7583-93. [Abstract] [Full-text]
19. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
    Leuk Lymphoma, 46(11): 1667-70. [Abstract] [Full-text]
20. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
    Ann Oncol, 16(11): 1811-6. [Abstract] [Full-text]
21. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
    Blood, 106(9): 3206-13. [Abstract] [Full-text]
22. Gastrointestinal stromal tumor: 5 years later.
    Cancer, 104(9): 1781-8. [Abstract] [Full-text]
23. Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
    Leukemia, 19(11): 1872-9. [Abstract] [Full-text]
24. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
    Leukemia, 19(11): 1896-904. [Abstract] [Full-text]
25. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
    Leukemia, 19(11): 1905-11. [Abstract] [Full-text]
26. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.
    Leukemia, 19(11): 1859-62. [Abstract] [Full-text]
27. Immunohistochemical analysis of desmoid tumours.
    J Clin Pathol, 58(11): 1152-6. [Abstract] [Full-text]
28. The hypereosinophilic syndromes: still more heterogeneity.
    Curr Opin Immunol, 17(6): 679-84. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.